Quantitative analysis of the arterial network is a major challenge for surgeons and radiologists. Until today, no fully automated solution for extracting various criteria necessary for the diagnosis, planning and surgical monitoring of arterial pathologies has ever been commercialized. Nurea, a start-up from Bordeaux created in 2018 and specialized in cardiovascular preventive medicine, has developed in response to these needs the PRAEVAorta® 2 software solution. This state-of-the-art IA based software helps to improve the diagnosis, planning and monitoring of aortic aneurysms. Developed in partnership with Pr. Eric Ducasse, Chief of vascular surgery at CHU Pellegrin in Bordeaux, it has just obtained CE marking.
Surgical planning report generated by PRAEVAorta®2
Thanks to its AI and automatic calculation algorithms, PRAEVAorta® 2 is fully automated and easily integrated into existing tools (PACS, viewers...). From all scanner images, regardless of the use of contrast agents, it allows the extraction of the different criteria (1) necessary for the diagnosis, surgical planning and monitoring of aortic pathologies. This innovation not only allows for a complete mapping of the aorta, but also detects the presence of diseases or potentially unintended adverse events.
PRAEVAorta® 2 helps to perform faster (95% time savings per examination(1)) and safer diagnostic, by standardizing measurements between radiologists and surgeons. This innovation has been tested by a dozen hospitals around the world and has already been the subject of two scientific publications in 2021/2022 (2,3).
Aortic biomarkers generated by PRAEVAorta®2
"Nurea's ambition is to revolutionize the treatment and monitoring of cardiovascular diseases. The CE certification of PRAEVAorta® 2 is a major milestone in the company's development, allowing for the launch of commercialization in Europe and the possibility for hundreds of radiologists and surgeons to benefit from the innovation of the PRAEVAorta® 2 solution," said Florian Bernard, president and co-founder of Nurea.
In terms of commercial development, Nurea has already signed partnerships with GE Healthcare (Start-up program Edison) and Intrasense (part of the Guerbet group) in 2022 and 2023. Thanks to these agreements, PRAEVAorta® 2 will have the opportunity to be integrated into software suites used by thousands of hospitals worldwide. These partnerships will thus allow for a strong acceleration of commercialization at the European level. Nurea is also working on FDA approval for commercialization in the United States in 2024.
<aside> 💡 Nurea obtains CE marking for PRAEVAorta® 2 (Class IIb). It is thus one of the first actors to obtain CE marking according to the modalities of the new European regulation. Obtaining the CE marking testifies to Nurea's commitment to the most rigorous quality, safety and performance standards. This recognition confirms that PRAEVAorta® 2 meets the strict necessary requirements for its use in clinical environments, thus paving the way for wider adoption of this innovative solution by healthcare professionals.
</aside>
Cardiovascular diseases, a major public health issue: